Why the study?
Does biologic therapy reduce coronary inflammation assessed by perivascular FAI in patients with moderate to severe psoriasis?
Does biologic therapy reduce coronary inflammation assessed by perivascular FAI in patients with moderate to severe psoriasis?
Biologic therapy in psoriasis patients is associated with reduced coronary inflammation, suggesting perivascular FAI via CCTA could track responses to interventions for coronary artery disease.
Supports FAI as a potential response marker for biologic therapy in psoriasis; hypothesis-generating and requires prospective validation.
In this study, biologic therapy for moderate to severe psoriasis was associated with reduced coronary inflammation assessed by perivascular FAI. This finding suggests that perivascular FAI measured by CCTA may be used to track response to interventions for coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Elnabawi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: